Aims
The main objective of this work was to evaluate the influence of end-stage renal disease (ESRD) on concentrations of five tumor markers (TMs): carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9 (CA19-9), CA15-3, CA125, and prostate specific antigen (PSA) in a group of chronic hemodialysis patients (CHPs); and to study the influence of hemodialysis (HD) sessions on concentrations of the same TMs.
Methods
We compared TMs levels in CHP before HD sessions to a control group of 50 healthy volunteers, the dosages were determined before and immediately after the HD session Comparisons were made before and after correction for dialysis-induced hemoconcentrations.
Results
We enrolled 74 CHPs, all TM concentrations were higher in this group compared to control group, but this increase was significant for CEA (4.25 ± 2.89 vs 2.41 ± 1.81ng/ml; p<0.0001), CA125 (27.84 ± 92.27 vs 13.30 ± 9.85 ng/ml; p = 0.048) and CA19-9 (19.65 ± 25.02 vs 10.23 ± 11.00 U/ml; p = 0.011). Post-dialysis levels were significantly higher than those in pre-dialysis. CEA (3.35 [2,46-5.51] vs 4,06 [2.60-6.78] ng/ml; p<0.0001), CA125 (13.24 [9.66-18.63] vs 16.01 [11.33-22.53] ng/ml; p<0.0001), CA19-9 (12.29 [5.59-21.97] vs 16.29 [7.18-24.7] U/ml; p<0.0001), CA15-3 (13.06 [10.05-17.48] vs 14.58 [11.72-19.35] ng/ml; p<0.0001 and PSA (0.83 [0.5-1.24] vs 1.06 [0.62-1.43] ng/ml; p<0.0001).
Conclusions
Our work confirms that HD increases concentrations of the five TMs evaluated and suggests that the use of CA15-3 and PSA remains valid in CHPs since their concentrations were not altered by ESRD, unlike CEA, CA125, and CA19-9.
RÉSUMÉ Nous avons déterminé la prévalence du syndrome métabolique chez 25 hémodialysés chroniques dans le centre d'hémodialyse chronique de l'hôpital militaire d'instruction Mohammed V de Rabat (Maroc). L'âge moyen des patients était de 46,5 ans (écart type [ET] 14,48) et la durée moyenne en hémodialyse était de 62,9 mois (ET 38,4). Nous avons évalué les cinq paramètres du syndrome métabolique : tour de taille, hypertriglycéridémie, cholestérol HDL (lipoprotéines de haute densité), pression artérielle et glycémie. Au total, 11 patients (44 %) avaient un syndrome métabolique : 7 femmes et 4 hommes. Un taux bas de cholestérol HDL a été retrouvé chez 100 % des patients, une hypertriglycéridémie chez 90,9 % et une hypertension artérielle chez 63,6 %. Il y avait une différence significative entre les patients avec syndrome métabolique et ceux sans syndrome métabolique concernant les niveaux de l'hypertriglycéridémie et du cholestérol HDL, et le tour de taille. Les facteurs associés significativement à la présence du syndrome métabolique étaient l'obésité abdominale, l'hypertension artérielle systolique et l'hypertriglycéridémie.
Prevalence of metabolic syndrome in chronic haemodialysis patients in MoroccoWe determined the prevalence of metabolic syndrome in 25 chronic haemodialysis patients in the haemodialysis centre of the Mohammed V military teaching hospital in Rabat. The mean age of the patients was 46.5 (SD 14.8) years and mean haemodialysis duration 62.9 (SD 38.4) months. We evaluated the 5 parameters of metabolic syndrome: waist circumference, hypertriglyceridaemia, high-density lipoprotein (HDL) cholesterol, blood pressure and blood glucose. In all, 11 (44%) patients had metabolic syndrome: 7 women and 4 men. Low HDL cholesterol was found in 100% of the patients, hypertriglyceridaemia in 90.9% and hypertension in 63.6%. There were significant differences between patients with and without metabolic syndrome with regard to levels of hypertriglyceridaemia and HDL cholesterol, and waist circumference. Factors significantly associated with the presence of metabolic syndrome were abdominal obesity, and systolic hypertension and hypertriglyceridaemia.املتوسط لرشق الصحية املجلة عرش السابع املجلد األول العدد 57
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.